



Reassessing the role of the neutrophil-to-lymphocyte ratio in chronic kidney disease patients

Yu Ho Lee

Division of Nephrology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea

See Article on Page 725-733

Chronic kidney disease (CKD) is characterized by an irreversible decline in kidney function and affects more than 10% of the general population worldwide [1]. Identifying patients at risk for rapid CKD progression is crucial as residual kidney function is an independent predictor of cardiovascular and all-cause mortality [2]. Among the various pathophysiological factors related to CKD, inflammation plays crucial roles in disease initiation and progression. Recently, the neutrophil-to-lymphocyte ratio (NLR) in peripheral blood has emerged as a promising prognostic indicator for various medical conditions, including infection, cardiovascular diseases, and malignancy [3-5]. It reflects the balance between acute and chronic inflammation and adaptive immunity. A high NLR indicates a heightened systemic inflammatory response and high risk for adverse clinical outcomes. By reflecting the balance between inflammation and the immune response, NLR predicts disease progression and severity, thereby facilitating treatment selection. As a result, NLR has become a valuable tool for CKD management and prognostication.

As reported in the current issue of the *Korean Journal of Internal Medicine*, Kim et al. [6] retrospectively investigated the clinical relevance of NLR in 141 patients with non-dialysis-dependent CKD. They found that patients in the third NLR tercile had lower estimated glomerular filtration rates (eGFRs) and greater proteinuria compared to those in the first tercile, in line with a previous study [7]. Importantly, the risk for composite kidney events, defined as a decline in the eGFR of $\geq 50\%$ or the initiation of renal replacement therapy, was significantly higher in patients with the highest NLR than in those with the lowest NLR, even after adjusting for possible confounders, including baseline serum levels cre-

atinine and proteinuria (adjusted hazard ratio = 3.33, 95% confidence interval = 1.43–7.76). Overall, these findings suggest that high NLR values are not only associated with reduced baseline kidney function but also independent indicators of sustained kidney injury and rapid CKD progression.

The association between NLR and high-sensitivity C-reactive protein (hs-CRP) level is important. Previous studies have found that hs-CRP levels are a useful indicator of systemic inflammation and adverse clinical outcomes in both the general population and CKD patients [8,9]. In Kim et al. [6], the hs-CRP levels were elevated in patients in the second and third NLR tercile. However, linear regression analysis showed no significant association between NLR values and hs-CRP levels, suggesting that the increased NLR values may not be solely due to systemic inflammation in CKD patients. In line with this, NLR values can be used to independently stratify risk among patients with heart disease, regardless of hs-CRP levels [10,11].

Kim et al. [6] also demonstrated an association between NLR terciles and rapid kidney function decline but not all-cause mortality, which does not align with the findings of a meta-analysis that showed that NLR predicted the risk of death in CKD patients [12]. This discrepancy can be attributed to several factors in their study, such as the retrospective study design, limited sample size, different cut-off values, and patient heterogeneity. Nonetheless, it is important to note that the cumulative incidence of all-cause mortality was elevated in patients in the second and third NLR terciles compared to those in the first NLR tercile. These discrepancies underscore the need for further well-designed studies with larger sample sizes.

In conclusion, the results of Kim et al. [6] emphasize the clinical significance of NLR in risk stratification and the selection of personalized treatment for progressive kidney dysfunction in CKD patients. NLR is a simple and cost-effective

indicator, making its use suitable for routine clinical practice. It can help improve patient outcomes and optimize CKD management. Further research is needed to verify its clinical usefulness for CKD management and to ensure its reliability as an independent prognostic marker for CKD.

REFERENCES

1. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. *Kidney Int Suppl* (2011) 2022;12:7-11.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004;351:1296-1305.
3. Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. *BMC Med* 2020;18:360.
4. de Jager CP, van Wijk PT, Mathoera RB, et al. Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. *Crit Care* 2010;14:R192.
5. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. *Am J Cardiol* 2008;102:653-657.
6. Kim J, Song SH, Oh TR, et al. Prognostic role of the neutrophil-to-lymphocyte ratio in patients with chronic kidney disease. *Korean J Intern Med* 2023 Aug 17 [Epub]. DOI: 10.3904/kjim.2023.171.
7. Tatar E, Mirili C, Isikyakar T, et al. The association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with clinical outcomes in geriatric patients with stage 3-5 chronic kidney disease. *Acta Clin Belg* 2016;71:221-226.
8. Li Y, Zhong X, Cheng G, et al. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis. *Atherosclerosis* 2017;259:75-82.
9. Lee C, Park KH, Joo YS, et al. Low high-sensitivity c-reactive protein level in Korean patients with chronic kidney disease and its predictive significance for cardiovascular events, mortality, and adverse kidney outcomes: results from KNOW-CKD. *J Am Heart Assoc* 2020;9:e017980.
10. Wada H, Dohi T, Miyauchi K, et al. Neutrophil to lymphocyte ratio and long-term cardiovascular outcomes in coronary artery disease patients with low high-sensitivity c-reactive protein level. *Int Heart J* 2020;61:447-453.
11. Ding B, Liu P, Zhang F, Hui J, He L. Predicting values of neutrophil-to-lymphocyte ratio (NLR), high-sensitivity C-reactive protein (hs-CRP), and left atrial diameter (LAD) in patients with nonvalvular atrial fibrillation recurrence after radiofrequency ablation. *Med Sci Monit* 2022;28:e934569.
12. Zhao WM, Tao SM, Liu GL. Neutrophil-to-lymphocyte ratio in relation to the risk of all-cause mortality and cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis. *Ren Fail* 2020;42:1059-1066.

Received : August 8, 2023
Accepted : August 19, 2023

Correspondence to

Yu Ho Lee, M.D., Ph.D.
 Division of Nephrology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Bundang-gu, Seongnam 13496, Korea
 Tel: +82-31-780-5025, Fax: +82-31-780-5219
 E-mail: borywork@hanmail.net
<https://orcid.org/0000-0001-5231-0551>

Conflicts of interest

The author discloses no conflicts.

Funding

None